Comparative Pharmacology
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE versus DRIXORAL PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE versus DRIXORAL PLUS.
DIPHENHYDRAMINE HYDROCHLORIDE vs DRIXORAL PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H1 receptors, reducing allergic symptoms; also exerts anticholinergic, sedative, and antiemetic effects via central and peripheral receptor blockade.
DRIXORAL PLUS contains dexbrompheniramine, an antihistamine that competes with histamine for H1-receptor sites, suppressing histamine-induced symptoms; and pseudoephedrine, a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
25-50 mg orally or intramuscularly every 4-6 hours as needed; maximum 300 mg per day.
1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life 4–10 hours (mean ~7 hours); prolonged in elderly, hepatic impairment, and with CYP2D6 poor metabolizers.
Pseudoephedrine: ~9-16 hours (pH-dependent, longer in alkaline urine). Dexbrompheniramine: ~20-25 hours. Clinical context: multiple dosing accumulates.
Renal elimination of metabolites accounts for ~60% of the dose; <5% excreted unchanged. Fecal excretion ~40% via bile.
Renal: 50-70% unchanged for pseudoephedrine; hepatic metabolism for dexbrompheniramine with renal excretion of metabolites.
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant